In the latest episode of Pathfinders, our Healthcare technology analyst Sean Dodge explores a quiet but accelerating revolution in the way US healthcare works – and the new breed of companies poised to benefit.

In this latest episode, our head of biotech research Brian Abrahams shares a big picture analysis of the industry, outlining the long-term disruptions and opportunities ahead for biotech.

In the latest episode of Pathfinders, Noël Brown, Head of US Biotechnology Investment Banking at RBC Capital Markets, reveals why he’s feeling optimistic about M&A in biopharma and how leading in biotech investment and corporates needs visionary long-term thinking.

In this episode, Dr. Chen Yu, Founder and Managing Partner at TCG X and Noël Brown, Head of U.S. Biotechnology Investment Banking at RBC Capital Markets, discuss why they remain optimistic about biotech and what’s happening behind the scenes in public and private markets.

How are top investors navigating the longest biotech bear market in almost 20 years? RBC Capital Markets Healthcare Desk Sector Strategist Chris McCarthy talks to HealthCor’s Ben Snedeker and Omega Funds founder Otello Stampacchia to find out.

What does it take to tackle the most perplexing orphan diseases? Ted W. Love, M.D., President and CEO, Global Blood Therapeutics (GBT), speaks with RBC Capital Markets’ Senior Biotechnology Analyst Gregory Renza, M.D., about having a mission and the drive to succeed on this episode of Pathfinders.

In this episode of Pathfinders, Luca Issi, Senior Biotech Analyst at RBC Capital Markets, speaks with Beth Hougen, CFO of Ionis – a leading innovator in the development of antisense medicines and RNA-targeted therapeutics – to find out how the firm is embedding ESG into its vision, strategy and performance.

As biotech firms and large pharma companies find new synergies to bring new treatments to market together, Noël Brown, Managing Director and Head of US Biotechnology Investment Banking at RBC Capital Markets, interviews pharma industry veteran, now Biopharma Managing Director, Greg Wiederrecht on what it takes to ensure a strategic partnership not only survives, but thrives.

For biopharma companies, ESG commitments can look considerably different from other sectors. We spoke with the team of ESG leads at Gilead Sciences to understand the five key components driving its ESG strategy, how it’s evolved and how it impacts their business. 

RBC Capital Markets’ Noël Brown, Head of US Biotech Investment Banking, goes behind the scenes of one of the biggest biotech SPAC deals of the year with NuvationBio Founder and CEO, Dr. David Hung and Omega Funds Partner and President of its Omega Alpha SPAC, Michelle Doig. These two industry leaders at the cutting edge of biotech innovation and venture capital share how they brought NuvationBio’s public market vision to fruition on the latest episode of RBC’s Pathfinders podcast.